iwNHL 2018 Session VII

CAR-T in Lymphoma

Session VII of iwNHL 2018 saw David Maloney, MD, PhD, James Kochenderfer, MD, Bianca Santomasso, MD, PhD and Stephen Schuster, MD discuss CAR-T cell therapy and associated issues of toxicity and task of commercialization.

Presentations
Off to the CAR-T Races
David Maloney
Fred Hutchinson Cancer Research Center, Seattle, Washington
23 September, 2018

David Maloney, MD, PhD, from Fred Hutchinson Cancer Research Center, Seattle, Washington, speaks on CD19-directed CAR-T cell therapies.

Current Standard for Treatment & Prevention of Toxicities Related to CAR-T
James Kochenderfer
The National Cancer Institute, Rockville, MD
23 September, 2018

James Kochenderfer, MD from The National Cancer Institute, Rockville, MD, talks about the management of CAR-T cell therapy-related toxicities.

Neurotoxicity
Bianca Santomasso
Memorial Sloan Kettering Cancer Center, New York City, NY
23 September, 2018

Bianca Santomasso, MD, PhD from Memorial Sloan Kettering Cancer Center, New York City, NY, speaks on neurotoxic events associated with CAR-T cell therapy.

Anti-CD19 CAR-T Cells in Aggressive NHL
Stephen Schuster
University of Pensylvania, Philadelphia, PA
23 September, 2018

Steve Schuster, MD, from University of Pennsylvania, Philadelphia, PA, talks about the use of anti-CD19 CAR-T cells in aggressive non-Hodgkin lymphoma,